Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Preston, Australia Clinical Trials

A listing of Preston, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (672) clinical trials

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

1.96 miles

Learn More »

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (SELECT-PsA 2)

This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of ABT-494 Dose A once daily (QD) and Dose B QD versus placebo in participants with moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response ...

Phase

2.13 miles

Learn More »

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug

This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of ABT-494 Dose A once daily (QD) and Dose B QD versus placebo and versus adalimumab every other week (eow) in participants with moderately to severely active Psoriatic ...

Phase

2.13 miles

Learn More »

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The primary efficacy assessment will ...

Phase

2.13 miles

Learn More »

A Phase II Study to Assess the Safety Tolerability and Efficacy of Xanamem in Subjects With Mild Dementia Due to AD (XanADu)

This is a Phase II, randomised, multi-centre, double-blind, placebo-controlled proof-of-concept study to assess the safety, tolerability and efficacy of oral Xanamem once daily in adult subjects with mild dementia due to AD. Based on Xanamem's mode of action on hippocampal function, amnestic symptoms may respond best, thus favouring the inclusion ...

Phase

2.13 miles

Learn More »

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected ...

Phase

2.13 miles

Learn More »

An Open-Label Crenezumab Study in Patients With Alzheimer's Disease

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg IV Q4W will be offered to all patients who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in patients on long-term crenezumab treatment and to investigate the effect of crenezumab on ...

Phase

2.13 miles

Learn More »

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary ...

Phase

2.13 miles

Learn More »

Multinational Clinical Study Comparing Isatuximab Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

The duration of the study for the patients will include a period for screening of up to 3 weeks. Patients will continue study treatment until disease progression, unacceptable adverse reaction, patients' wish or other reason of discontinuation. During follow-up, patients who discontinue the study treatment due to progression of the ...

Phase

2.13 miles

Learn More »

Clinical Benefit of SAR650984 Bortezomib Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant

The duration of the study for each patient will include a screening period of up to 4 weeks, an induction period of 24 weeks (4 cycles with a duration of 42 4 days), a continuous treatment period and a crossover period (when applicable). The cycle duration is 28 4 days ...

Phase

2.13 miles

Learn More »